Monkey Pox Treatment Market Report 2026

Monkey Pox Treatment Market Overview

• Monkey Pox Treatment market size has reached to $0.1 billion in 2025 • Expected to grow to $0.18 billion in 2030 at a compound annual growth rate (CAGR) of 13% • Growth Driver: Rising Zoonotic Cases Fuel Market Growth For Monkeypox Treatment • Market Trend: New Antiviral Breakthrough Strengthens Global Preparedness Against Emerging Orthopox Threats • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Monkey Pox Treatment Market?

Monkeypox treatment refers to the medical interventions and therapies used to manage and alleviate the symptoms of monkeypox, a viral disease caused by the monkeypox virus. It encompasses a range of therapeutic and supportive approaches aimed at reducing the severity of the disease and improving patient outcomes. The main types of monkey pox treatment include prophylactic vaccines and therapeutics. Prophylactic vaccines are designed to prevent monkeypox infection by stimulating the immune system to recognize and fight the monkeypox virus if exposed in high-risk populations and during outbreaks to control the spread of the virus. The dosage forms include solid, liquid, and semisolid, with routes of administration types such as oral, topical, and parenteral. The distribution channels include retail pharmacies, hospital pharmacies, and online pharmacies.

What Is The Monkey Pox Treatment Market Growth Forecast?

The monkey pox treatment market size is expected to see rapid growth in the next few years. It will grow to $0.18 billion in 2030 at a compound annual growth rate (CAGR) of 13.0%. The growth in the forecast period can be attributed to expansion of antiviral pipeline, rising global vaccination initiatives, increased funding for infectious disease research, adoption of improved diagnostic tools, growing government preparedness programs. Major trends in the forecast period include expansion of precision-based antiviral development, adoption of AI-powered outbreak forecasting models, growth of digital tracking systems for case monitoring, increasing use of iot-enabled disease surveillance networks, rising demand for sustainable vaccine production processes.

Global Monkey Pox Treatment Market Segmentation

1) By Treatment Type: Prophylactic Vaccines, Therapeutics 2) By Dosage Forms: Solid, Liquid, Semi Solid 3) By Route Of Administration: Oral, Topical, Parenteral 4) By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, Online Pharmacies Subsegments: 1) By Prophylactic Vaccines: Vaccinia-Based Vaccines, Modified Vaccinia Ankara (MVA) Vaccines 2) By Therapeutics: Antiviral Agents (Tecovirimat, Brincidofovir), Immune Modulators, Supportive Care Treatments

What Is The Driver Of The Monkey Pox Treatment Market?

The increasing prevalence of zoonotic infection is expected to propel the growth of the monkeypox treatment market going forward. A zoonotic infection is a disease that is transmitted from animals to humans through direct contact with contaminated environments or vectors. With increased human-animal interaction by bringing people and animals into closer contact raises zoonotic infection risks. Moreover, climate change worsens this risk by expanding disease vector ranges and introducing pathogens to new areas. Monkeypox treatments are used to manage zoonotic mpox by targeting the virus and alleviating symptoms in both humans and potentially infected animals. For instance, in August 2024, according to a report published by the UK Health Security Agency, a UK-based government agency, there were 3,732 confirmed mpox cases in the UK, rising by 21 more in 2023 with 3753 cases. Therefore, the increasing prevalence of zoonotic infection drives the monkeypox treatment market.

Key Players In The Global Monkey Pox Treatment Market

Major companies operating in the monkey pox treatment market are Merck & Co Inc, Sanofi S A, Gilead Sciences Inc, BioNTech SE, Moderna Inc, Novavax Inc, Emergent BioSolutions Inc, Bavarian Nordic A S, SIGA Technologies Inc, Tonix Pharmaceuticals Holding Corp, Chimerix Inc, Emcure Pharmaceuticals Ltd, VBI Vaccines Inc, Pfizer Inc, Regeneron Pharmaceuticals Inc, GeoVax Labs Inc, Zydus Cadila Ltd, Serum Institute of India Pvt Ltd, Biological E Ltd, Dr Reddy’s Laboratories Ltd, Hester Bioscience Ltd, Indian Immunologicals Ltd, Reliance Life Sciences Pvt Ltd, Takeda Pharmaceuticals Co Ltd, KM Biologics Co Ltd, Meridian Bioscience Inc, NanoViricides Inc.

Global Monkey Pox Treatment Market Trends and Insights

Major companies operating in the monkeypox treatment market are focusing on developing innovative products such as small-molecule antivirals to enhance global health preparedness and stockpiling capacity. Small-molecule antivirals inhibit specific viral proteins to block virus spread within the body and can be stored long-term, making them ideal for emergency response. For instance, in January 2025, SIGA Technologies, a US-based pharmaceutical company, secured approval in Japan for TEPOXX (tecovirimat 200 mg capsules), marking the first antiviral to treat orthopoxviruses in that country. This product demonstrates a strong safety profile based on data from 15 clinical trials involving over 800 healthy volunteers, showed quantifiable pharmacokinetics within effective dose ranges, and exhibited robust preclinical efficacy in animal models where it reduced both mortality and viral load. The drug acts by inhibiting the VP37 protein on the virus surface, preventing viral exit from infected cells, enabling the immune system to clear the infection. SIGA has partnered with Japan Biotechno Pharma as its exclusive distributor to build Japan’s strategic national stockpile of TEPOXX.

What Are Latest Mergers And Acquisitions In The Monkey Pox Treatment Market?

In August 2024, Bilthoven Biologicals, a Netherlands-based provider of vaccines and biopharmaceutical products, partnered with Tonix Pharmaceuticals. The collaboration aims to accelerate the development of TNX-801 as a potential vaccine to prevent Mpox, smallpox, and other infectious diseases. Tonix Pharmaceuticals is a US-based pharmaceutical company engaged in developing monkey pox treatment vaccines.

Regional Outlook

North America was the largest region in the monkey pox treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Monkey Pox Treatment Market?

The monkey pox treatment market consists of sales of treatment products such as antiviral medications, vaccine administration devices, supportive care products, infection control supplies, and Reagents and assays for monkeypox research and diagnostic development. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Monkey Pox Treatment Market Report 2026?

The monkey pox treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the monkey pox treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.